23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Mirum Pharmaceuticals, Inc. › 2025-2026

Mirum Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Mirum Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 347Asset managers, any item
  • 2,098Fund votes
  • June 15, 2026Meeting date

Results at a glance

Meeting of June 15, 2026: 5 items on Mirum Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 3 elected · 2 approved.

Dissent

Significant dissent: 1 director (30.3% against).

Notable dissent: 2 directors (14.7%, 13.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13F, 1.9%, as of September 30, 2026)

Explore Mirum Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Mirum Pharmaceuticals, Inc.

These tallies are Mirum Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Mirum Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 15, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Lon Cardon, Ph.D., FMedSci 39,587,327---- 6,827,2143,614,839 85%Elected—
Elect Director: William Fairey 40,266,848---- 6,147,6933,614,839 87%Elected—
Elect Director: Timothy Walbert 32,329,718---- 14,084,8233,614,839 70%Elected—
2. Ratification of the Selection of Independent Registered Public Accounting Firm 49,993,5145,67430,192 ---- 99.9%Approved—
3. Advisory Vote on Executive Compensation 44,534,5751,866,71913,247 --3,614,839 96%Approved—

Source: Mirum Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Mirum Pharmaceuticals, Inc. 2025-2026 meeting

347 asset managers disclosed a vote on at least one Mirum Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Lon Cardon, Ph.D., FMedSci

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 39,587,327WITHHELD: 6,827,214
Details: description as filed, official tally, votes by 108 asset managers

Description as filed by funds: To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSci

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Lon Cardon, Ph.D., FMedSci”): 39,587,327 for, 6,827,214 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 108 asset managers below reported 18,796,478 for, 2,715,516 withheld, 15 abstained.

FOR
FOR: 18,796,478ABSTAIN: 15WITHHOLD: 2,715,516
Largest asset managers voting on “To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meetin” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,996,1950 1515,615For
Fidelity3,343,6630 0400For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,430,8780 00For
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,018,0420 01,170For
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett00 0377,552Withhold
Legg Mason373,6150 02,776For
Federated Hermes348,0280 00For
Loomis Sayles00 0259,022Withhold
Waddell & Reed00 0234,817Withhold
Bridge Builder Trust130,5390 080,972Mixed
Invesco211,4010 00For
Erste Asset Management GmbH00 0210,000Withhold
MFS00 0198,836Withhold
BNY Mellon156,0350 01,449For
RBB FUND, INC.00 0156,154Withhold
Manager Directed Portfolios151,8710 00For
First Trust00 0127,079Withhold
Columbia Threadneedle121,3230 00For

Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).

Elect Director: Timothy Walbert

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD
FOR: 32,329,718WITHHELD: 14,084,823
Details: description as filed, official tally, votes by 108 asset managers

Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy Walbert

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Timothy Walbert”): 32,329,718 for, 14,084,823 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 108 asset managers below reported 14,838,879 for, 6,673,098 withheld, 31 abstained.

FORWITHHOLD
FOR: 14,838,879ABSTAIN: 31WITHHOLD: 6,673,098
Largest asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meet” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,994,0610 3117,733For
Fidelity3,326,4120 017,651For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock92,1250 01,338,753Mixed
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street2,0120 01,017,200Withhold
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab00 0427,375Withhold
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett00 0377,552Withhold
Legg Mason373,6150 02,776For
Federated Hermes348,0280 00For
Loomis Sayles00 0259,022Withhold
Waddell & Reed00 0234,817Withhold
Bridge Builder Trust122,5000 089,011Mixed
Invesco00 0211,401Withhold
Erste Asset Management GmbH00 0210,000Withhold
MFS00 0198,836Withhold
BNY Mellon00 0157,484Withhold
RBB FUND, INC.00 0156,154Withhold
Manager Directed Portfolios151,8710 00For
First Trust00 0127,079Withhold
Columbia Threadneedle00 0121,323Withhold

Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).

Elect Director: William Fairey

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 40,266,848WITHHELD: 6,147,693
Details: description as filed, official tally, votes by 108 asset managers

Description as filed by funds: To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: William Fairey

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William Fairey”): 40,266,848 for, 6,147,693 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 108 asset managers below reported 19,281,381 for, 2,230,614 withheld, 14 abstained.

FOR
FOR: 19,281,381ABSTAIN: 14WITHHOLD: 2,230,614
Largest asset managers voting on “To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meetin” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,996,1960 1415,615For
Fidelity3,336,1290 07,934For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,338,7530 092,125Mixed
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,018,0420 01,170For
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett00 0377,552Withhold
Legg Mason373,6150 02,776For
Federated Hermes348,0280 00For
Loomis Sayles259,0220 00For
Waddell & Reed00 0234,817Withhold
Bridge Builder Trust211,5110 00For
Invesco211,4010 00For
Erste Asset Management GmbH00 0210,000Withhold
MFS198,8360 00For
BNY Mellon156,0350 01,449For
RBB FUND, INC.00 0156,154Withhold
Manager Directed Portfolios151,8710 00For
First Trust00 0127,079Withhold
Columbia Threadneedle121,3230 00For

Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 44,534,575AGAINST: 1,866,719

Prior year: 96.0% for (May 29, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 347 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Mirum Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 44,534,575 for, 1,866,719 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 106 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,011,8223 00For
Fidelity3,344,0630 00For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,430,8780 00For
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,019,2120 00For
T. Rowe Price935,5100 00For
Capital Group0724,415 00Against
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett377,5520 00For
Legg Mason376,3910 00For
Federated Hermes348,0280 00For
Loomis Sayles259,0220 00For
Waddell & Reed234,8170 00For
Bridge Builder Trust211,5110 00For
Invesco211,4010 00For
MFS198,8360 00For
BNY Mellon1,449156,035 00Against
RBB FUND, INC.156,1540 00For
Manager Directed Portfolios151,8710 00For
First Trust127,0790 00For
Columbia Threadneedle0121,323 00Against
Equitable120,4130 00For

Fund voting reports, all 106 managers: 20,294,335 for, 1,001,840 against, 4,097 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 268 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson11,472,2570 00For
Fidelity2,479,0630 00For
State Street1,673,6700 00For
T. Rowe Price1,504,9960 00For
BVF INC/IL1,259,7270 00For
GEODE CAPITAL MANAGEMENT, LLC1,210,7770 00For
Novo Holdings A/S1,125,0000 00For
FRANKLIN ADVISERS INC790,6980 00For
BlackRock778,2760 00For
Capital Group0724,415 00Against
Rock Springs Capital Management LP701,6660 00For
Wellington692,6130 00For
Clearbridge Investments, LLC650,9610 00For
Paradigm Biocapital Advisors LP560,3050 00For
Polar Capital Holdings Plc535,5920 00For
RA CAPITAL MANAGEMENT, L.P.509,6860 00For
Federated Hermes494,7250 00For
LORD, ABBETT & CO. LLC484,8450 00For
Loomis Sayles447,2390 00For
Candriam S.C.A.434,6920 00For
Nuveen427,6530 00For
Charles Schwab427,5830 00For
Vanguard388,5210 00For
PICTET ASSET MANAGEMENT SA374,9000 00For
BOONE CAPITAL MANAGEMENT LLC356,2690 00For

Institutional-manager reports, all 268 managers: 36,800,553 for, 1,585,862 against, 106 abstained, 661 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 49,993,514AGAINST: 5,674

Prior year: 100.0% for (May 29, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 108 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Mirum Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 49,993,514 for, 5,674 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 108 asset managers below reported 21,507,912 for, 4,097 abstained.

FOR
FOR: 21,507,912ABSTAIN: 4,097
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at Mirum Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,011,8250 00For
Fidelity3,344,0630 00For
JANUS INVESTMENT FUND2,337,6610 00For
BlackRock1,430,8780 00For
MUTUAL FUND SERIES TRUST1,316,7390 00For
State Street1,019,2120 00For
T. Rowe Price935,5100 00For
Capital Group724,4150 00For
Charles Schwab427,3750 00For
TIAA400,7470 00For
FRANKLIN STRATEGIC SERIES377,9490 00For
Lord Abbett377,5520 00For
Legg Mason376,3910 00For
Federated Hermes348,0280 00For
Loomis Sayles259,0220 00For
Waddell & Reed234,8170 00For
Bridge Builder Trust211,5110 00For
Invesco211,4010 00For
Erste Asset Management GmbH210,0000 00For
MFS198,8360 00For
BNY Mellon157,4840 00For
RBB FUND, INC.156,1540 00For
Manager Directed Portfolios151,8710 00For
First Trust127,0790 00For
Columbia Threadneedle121,3230 00For

Showing the 25 largest of 108 asset managers. All 108 are in the interactive database (link above).

Largest Mirum Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,926,165 shares outstanding at the time of that meeting.

Fund voting reports: top Mirum Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 6.58%
2Fidelity 5.49%
3JANUS INVESTMENT FUND 3.84%
4BlackRock 2.35%
5MUTUAL FUND SERIES TRUST 2.16%
6State Street 1.67%
7T. Rowe Price 1.54%
8Capital Group 1.19%
9Charles Schwab 0.70%
10TIAA 0.66%
Institutional-manager reports: top Mirum Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 18.83%
2Fidelity 4.07%
3State Street 2.75%
4T. Rowe Price 2.47%
5BVF INC/IL 2.07%
6GEODE CAPITAL MANAGEMENT, LLC 1.99%
7Novo Holdings A/S 1.85%
8FRANKLIN ADVISERS INC 1.30%
9BlackRock 1.28%
10Capital Group 1.19%

Reported Mirum Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Mirum Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
JANUS HENDERSON GROUP Ltd.5,909,184 9.70%Schedule 13G, filed August 13, 2026
Patrick Heron4,108,404 6.74%Proxy statement (DEF 14A), table as of February 17, 2026
James N. Topper4,025,922 6.61%Schedule 13D, filed January 27, 2026
BlackRock3,846,530 6.31%Form 13F, quarter ended March 31, 2026
Frazier Life Sciences IX, L.P.3,566,912 5.85%Proxy statement (DEF 14A), table as of February 17, 2026
Vanguard Group2,596,089 4.26%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)1,965,375 3.23%Form 13F, quarter ended March 31, 2026
State Street1,944,281 3.19%Form 13F, quarter ended March 31, 2026
Christopher Peetz1,817,230 2.98%Proxy statement (DEF 14A), table as of February 17, 2026
T. Rowe Price1,717,421 2.82%Form 13F, quarter ended March 31, 2026

Percentages above are of 60,926,165 shares outstanding, as reported by Mirum Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Mirum Pharmaceuticals, Inc.'s shareholder meeting held June 15, 2026, in the 2025-2026 proxy season, 347 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,098 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Mirum Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Mirum Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mirum Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Mirum Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Mirum Pharmaceuticals (MIRM) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/mirum-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.